Medicaid Pharmacy and Therapeutics Committee Agenda for November 2, 2007

The Pharmacy & Therapeutics Committee will meet November 2, 2007, from 8:00 a.m. to 4:45 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York.

The Pharmacy and Therapeutics Committee will re-review each therapeutic class subject to the Preferred Drug Program (PDP) on an annual basis. This meeting will be devoted to the annual re-review of the therapeutic classes detailed below.

The Committee will review new clinical and financial information pertaining to the following therapeutic classes to determine preferred and non-preferred drugs in each class. The Committee will only consider clinical information which is new since the previous review of the therapeutic classes. New clinical information may include: new drug or drug product information, new indications, new safety information or new comparative clinical trials. Those wishing to submit new clinical information must do so at least two (2) weeks prior to the date of the meeting or the Committee may not have ample time to review the information.

1. Therapeutic class: Leukotriene Modifiers (Previous review date June 9, 2006)

Drugs Affected: Accolate (zafirlukast), Singulair (montelukast)

2. Therapeutic class: Hepatitis C Agents (Previous review date June 9, 2006)

Drugs Affected: PEG-Intron (peginterferon alfa-2b), Pegasys (peginterferon alfa-2a)

3. Therapeutic class: Cephalosporins - Third Generation (Previous review date Nov 10, 2006)

Drugs Affected: Cedax (ceftibuten), cefdinir, cefpodoxime proxetil, Omnicef (cefdinir), Suprax (cefixime), Spectracef (cefditoren), Vantin (cefpodoxime proxetil)

4. Therapeutic class: Fluoroquinolones - Otic (Previous review date Dec 8, 2006)

Drugs Affected: Cipro HC (ciprofloxacin/hydrocortisone), Ciprodex (ciprofloxacin/dexamethasone), Floxin (ofloxacin)

5. Therapeutic class: Anti-Emetics (Previous review date May 5, 2006)

Drugs Affected: Anzemet (dolasetron), Kytril (granisetron), ondansetron, Zofran (ondansetron)

6. Therapeutic class: Antihistamines - Second Generation (Previous review date June 9, 2006)

Drugs Affected: Allegra/Allegra-D (fexofenadine), Clarinex/Clarinex-D (desloratadine), Claritin/Claritin-D (loratadine), loratadine/loratadine D, fexofenadine, Semprex-D (acrivastine), Xyzal (levocetirizine), Zyrtec/Zyrtec-D (cetirizine)

7. Therapeutic class: Cholesterol Absorption Inhibitors (CAIs) (Previous review date Dec 8, 2006)

Drug Affected: Zetia (ezetimibe)

8. Therapeutic Class: Phosphate Binders/Regulators (Previous review date Sept 19, 2006)

Drugs Affected: Fosrenol (lanthanum), Phoslo (calcium acetate), Renagel (sevelamer)

9. Therapeutic Class: Beta2 Adrenergic Agents - Inhaled Short Acting (Previous review date Sept 19, 2006)

Drugs Affected: Accuneb (albuterol), albuterol, Alupent (metaproterenol), Maxair Autohaler (pirbuterol), metaproterenol, ProAir HFA (albuterol), Proventil (albuterol), Proventil HFA (albuterol), Ventolin HFA (albuterol), Xopenex (levalbuterol), Xopenex HFA (levalbuterol)

10. Therapeutic Class: Beta2 Adrenergic Agents - Inhaled Long Acting (Previous review date September 19, 2006)

Drugs Affected: Brovana (arformoterol), Foradil (formoterol), Perforomist (formoterol), Serevent Diskus (salmeterol)

11. Therapeutic class: Anticholinergics - Inhaled (Previous review date Sept 19, 2006)

Drugs Affected: Atrovent HFA (ipratropium), Combivent (ipratropium/albuterol), Duoneb (ipratropium/albuterol), ipratropium, ipratropium/albuterol, Spiriva (tiotropium)

12. Therapeutic Class: Corticosteroids - Inhaled (Previous review date Sept 19, 2006)

Drugs Affected: Advair Diskus (fluticasone/salmeterol), Advair HFA (fluticasone/salmeterol), Aerobid/Aerobid-M (flunisolide), Asmanex (mometasone), Azmacort (triamcinolone), Flovent Diskus (fluticasone), Flovent HFA (fluticasone), Pulmicort (budesonide) Turbuhaler, Pulmicort (budesonide) Flexhaler, Qvar (beclomethasone), Symbicort (budesonide/formoterol)

13. Therapeutic Class: Immunomodulators - Topical (Previous review date Sept 19, 2006)

Drugs Affected: Elidel (pimecrolimus), Protopic (tacrolimus)

14. Therapeutic Class: Anti-Fungals (Onychomycosis) (Previous review date Nov 10, 2006)

Drugs Affected: Fulvicin U/F (griseofulvin), Grifulvin V (griseofulvin), Gris-PEG (griseofulvin), griseofulvin, itraconazole, Lamisil (terbinafine), Penlac (ciclopirox), Sporanox (itraconazole), terbinafine

15. Therapeutic Class: Anti-Virals (used in the treatment of Herpes) (Previous review date Nov 10, 2006)

Drugs Affected: acyclovir, famciclovir, Famvir (famciclovir), Valtrex (valacyclovir), Zovirax (acyclovir)

16. Therapeutic class: Immunomodulators - Injectable (Previous review date Dec 8, 2006)

Drugs Affected: Enbrel (etanercept), Humira (adalimumab), Kineret (anakinra)

Schedule:

8:00 - 8:15 Welcome and Introductions
8:15 - 9:45 Public Comment Period*
10:00 - 12:00 Clinical Re-review of Leukotriene Modifiers, Hepatitis C Agents, Cephalosporins, Otic Fluoroquinolones, Anti-Emetics, Antihistamines, CAIs, Phosphate Binders/Regulators
12:00 - 1:30 Lunch Break/Executive Session (evaluation of trade secret supplemental rebate information)
1:30 - 1:45 Final Recommendations for preferred drugs in classes reviewed in the morning session
1:45 - 3:15 Clinical Re-review of Short and Long Acting Beta2 Adrenergic Agents, Anticholinergics, Corticosteroids, Topical Immunomodulators, Anti-Fungals, Anti-Virals, Injectable Immunomodulators
3:15 - 4:15 Afternoon Break/Executive Session (evaluation of trade secret supplemental rebate information)
4:15 - 4:30 Final Recommendations for preferred drugs reviewed in the afternoon session
4:30 - 4:45 DOH Update, Final Comments, and Adjournment

*Interested parties must notify DOH at least one (1) week prior to the meeting of their request to address the committee during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing ppno@health.state.ny.us (please reference P & T Committee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed 90 minutes. All written statements must be received at least one (1) week in advance of the meeting. Written statements should summarize key points and may not exceed two (2) pages in length.
NOTE: New clinical information must be submitted two (2) weeks prior to the date of the meeting.

Posted October 3, 2007